Post of the month... maybe the year? Next week should be

New Post Public Reply Private Reply Replies (0) Message Board
steelyeye farrell #65293
892
Post of the month... maybe the year?
Quote:

Next week should be a big week for IPIX. I am expecting an update from the company. The Trump administration is expected to announce its new Covid19 program with more emphasis on therapuetics such as Brilacidin. IMO they have come to the realization the vaccines are going to take a long time and they need encouraging Covid 19 treatment news before the election. My hope we have a good treatment before the election and Brilacidin is part of the answer.

Looking forward IPIX has many reasons to be optimistic. The last company update showed Brilacidin for OM is ready to enter a stage 3 FDA trial. Oral Brilacidin for Ulcerative Colitis has shown effective targeting of the colon and plans are being made for a stage 2 trial. Kevetrin demonstrated activation of p53 in its stage 2 trial.

www.ipharminc.com/new-blog/2020/6/25/u...-june-2020

Brilacidin for RBL studies using human pulmonary and renal cells confirmed it is effective in vitro against Covid19 (p<0.0001) and plans are being made to study its effects against MERS,Sars Viral encephalitis and other viruses.

In addition the RBL labs are moving forward to publish 2 peer review articles about Brilacidin's successful Coronavirus tests.

The RBL was so impressed it will assist Brilacidin's grant application: "testing results observed to date formed the basis for a federal grant application that was submitted last week by the RBL, in collaboration with the Company, proposing to evaluate Brilacidin’s potential as a pan-coronavirus therapeutic, with possible extension into other viruses"

http://www.ipharminc.com/press-release/2020/6...-cell-line

http://www.ipharminc.com/press-release/2020/6...herapeutic

It is important to remember the RBL labs are under Dr Fauci's NIAID. If any other therapeutic has had this level of independent testing and success against Covid 19 I am unaware of it being reported.

The next steps will be more funding, government grants, clinical trials.

We will see IPIX expand by hiring additional employees to manage the trials.

The stock price should increase with each step. I expect IPIX will be uplisted to a better exchange. After the clinical trials we should have a good idea of IPIX's value and at that stage I believe we will be looking at partners and /or licensing opportunities for Brilacidin for Covid 19, ulcerative Colitis and Oral mucositis.

Later IPIX should have funds to complete the Oral Kevetrin drug and begin clinical trials for Ovarian cancer and Acute Myelogenous Leukemia.

This time next year IPIX will be a very different company.

JMO GLTA Farrell

Read More: https://investorshangout.com/post/newpost/873...z6RNEpKGxZ

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Discover the Groundbreaking Midnight Soundbar by KEMIMOTO

Updated Category News Views 192

Transforming Outdoor Audio with the Midnight Soundbar KEMIMOTO, a well-known name in the UTV audio gear industry, has recently launched its latest offering: the Midnight Soundbar. This innovative soundbar isn't just about playing your favorite tracks; it's crafted for outdoor enthusiasts looking to enhance their experiences. With its waterproof and dustproof design, this...

Continue Reading
Market Insights: Shifting Dynamics and Economic Indicators

Updated Category News Views 141

Understanding Market Movements As markets worldwide brace for pivotal moments, there is a palpable tension in the air, particularly with the upcoming elections casting long shadows. Recent events, including insights from polling data, have startled investors and economic analysts alike. The Impact of Polling Data This past weekend, a poll surfaced, highlighting a...

Continue Reading
ORIC Pharmaceuticals Delivers Strong Q4 2024 Performance Update

Updated Category News Views 178

ORIC Pharmaceuticals Makes Significant Strides in Q4 2024 ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC), a leading player in the oncology therapeutic space, has shared some impressive updates regarding their financial results and operational progress during the fourth quarter and full year 2024. The company’s ongoing commitment to innovating cancer treatments is clearly...

Continue Reading
Exploring Opportunities in the Growing Ostomy Care Accessory Market

Updated Category News Views 113

Ostomy Care Accessory Market Growth Overview The global ostomy care accessory market is on track to achieve a remarkable valuation, projected to hit US$ 1,287.9 million by the end of 2034. This anticipates a strong growth trajectory, forecasting a compound annual growth rate (CAGR) of 7.5% from US$ 626.5 million in 2024. Such growth is primarily fueled by advancements in...

Continue Reading
Exciting New Retailers Transform The Bristol at Southport

Updated Category News Views 197

New Retailers Join The Bristol at Southport Exciting developments are taking place at The Bristol, located on the scenic shores of Lake Washington. A trio of fresh retail offerings is now open, adding vibrant options for residents and visitors alike. Core Havn, Soak and Sage, and Southport Kitchen and Market are the latest additions, complementing existing favorites such...

Continue Reading